Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation

Mydecine Innovations Group MYCO MYCOF has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, to study the application of psychedelics molecules and therapies in smoking cessation.

The research will be led by Dr. Matthew W. Johnson, professor of Psychiatry and Behavioral Sciences at Johns Hopkins.

The deal will allow Johns Hopkins and Mydecine to collaborate their efforts to advance research on novel psychedelic therapies to treat mental health and addiction disorders.

“Despite the recent attention to opiate and dependence on other illicit substances, we sometimes forget about the incredible burden that nicotine dependence has on our societies,” said Dr. Rakesh Jetly, chief medical officer at Mydecine.

Further details on the deal’s specific terms or the research to be conducted were not disclosed.

Photo: Andres Simon on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisPenny StocksMarketsDr. Matthew W JohnsonDr. Rakesh JetlyJohns Hopkins UniversityPsychedelics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!